Cathrine Mihalopoulos1, Lidia Engel2, Long Khanh-Dao Le2, Anne Magnus2, Meredith Harris3,4, Mary Lou Chatterton2. 1. School of Health and Social Development, Deakin Health Economics, Deakin University, Locked Bag 20001, Geelong, VIC, 3220, Australia. cathy.mihalopoulos@deakin.edu.au. 2. School of Health and Social Development, Deakin Health Economics, Deakin University, Locked Bag 20001, Geelong, VIC, 3220, Australia. 3. School of Public Health, The University of Queensland, Herston, QLD, 4006, Australia. 4. Policy and Epidemiology Group, Queensland Centre for Mental Health Research, Wacol, QLD, 4076, Australia.
Abstract
PURPOSE: High prevalence mental disorders including depression, anxiety and substance use disorders are associated with high economic and disease burden. However, there is little information regarding the health state utility values of such disorders according to their clinical severity using comparable instruments across all disorders. This study reports utility values for high prevalence mental disorders using data from the 2007 Australian National Survey of Mental Health and Wellbeing (NSMHWB). METHODS: Utility values were derived from the AQoL-4D and analysed by disorder classification (affective only (AD), anxiety-related only (ANX), substance use only (SUB) plus four comorbidity groups), severity level (mild, moderate, severe), symptom recency (reported in the past 30 days), and comorbidity (combination of disorders). The adjusted Wald test was applied to detect statistically significant differences of weighted means and the magnitude of difference between groups was presented as a modified Cohen's d. RESULTS: In total, 1526 individuals met criteria for a 12-month mental disorder. The mean utility value was 0.67 (SD = 0.27), with lower utility values associated with higher severity levels and some comorbidities. Utility values for AD, ANX and SUB were 0.64 (SD = 0.25), 0.71 (SD = 0.25) and 0.81 (SD = 0.19), respectively. No differences in utility values were observed between disorders within disorder groups. Utility values were significantly lower among people with recent symptoms (within past 30 days) than those without; when examined by diagnostic group, this pattern held for people with SUB, but not for people with ANX or AD. CONCLUSIONS: Health state utility values of people with high prevalence mental disorders differ significantly by severity level, number of mental health comorbidities and the recency of symptoms, which provide new insights on the burden associated with high prevalence mental disorders in Australia. The derived utility values can be used to populate future economic models.
PURPOSE: High prevalence mental disorders including depression, anxiety and substance use disorders are associated with high economic and disease burden. However, there is little information regarding the health state utility values of such disorders according to their clinical severity using comparable instruments across all disorders. This study reports utility values for high prevalence mental disorders using data from the 2007 Australian National Survey of Mental Health and Wellbeing (NSMHWB). METHODS: Utility values were derived from the AQoL-4D and analysed by disorder classification (affective only (AD), anxiety-related only (ANX), substance use only (SUB) plus four comorbidity groups), severity level (mild, moderate, severe), symptom recency (reported in the past 30 days), and comorbidity (combination of disorders). The adjusted Wald test was applied to detect statistically significant differences of weighted means and the magnitude of difference between groups was presented as a modified Cohen's d. RESULTS: In total, 1526 individuals met criteria for a 12-month mental disorder. The mean utility value was 0.67 (SD = 0.27), with lower utility values associated with higher severity levels and some comorbidities. Utility values for AD, ANX and SUB were 0.64 (SD = 0.25), 0.71 (SD = 0.25) and 0.81 (SD = 0.19), respectively. No differences in utility values were observed between disorders within disorder groups. Utility values were significantly lower among people with recent symptoms (within past 30 days) than those without; when examined by diagnostic group, this pattern held for people with SUB, but not for people with ANX or AD. CONCLUSIONS: Health state utility values of people with high prevalence mental disorders differ significantly by severity level, number of mental health comorbidities and the recency of symptoms, which provide new insights on the burden associated with high prevalence mental disorders in Australia. The derived utility values can be used to populate future economic models.
Authors: Jeffrey R J Richardson; Stuart J Peacock; Graeme Hawthorne; Angelo Iezzi; Gerald Elsworth; Neil A Day Journal: Health Qual Life Outcomes Date: 2012-04-17 Impact factor: 3.186
Authors: Long Khanh-Dao Le; Scott Richards-Jones; Mary Lou Chatterton; Lidia Engel; David Lawrence; Chris Stevenson; Genevieve Pepin; Julie Ratcliffe; Michael Sawyer; Cathrine Mihalopoulos Journal: Qual Life Res Date: 2021-05-17 Impact factor: 4.147
Authors: Long Khanh-Dao Le; Sophy Shih; Scott Richards-Jones; Mary Lou Chatterton; Lidia Engel; Christopher Stevenson; David Lawrence; Genevieve Pepin; Cathrine Mihalopoulos Journal: PLoS One Date: 2021-04-09 Impact factor: 3.240
Authors: Ishani K Majmudar; Cathrine Mihalopoulos; Bianca Brijnath; Michelle H Lim; Natasha Yvonne Hall; Lidia Engel Journal: Qual Life Res Date: 2022-01-24 Impact factor: 4.147